| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.909 | 0.002 | 0.964 | Phosphodiesterase IV inhibitor | 0.964 0.001 DBMET00997 | DBMET00997 | |
| 0.91 | 0.004 | 0.959 | Toll-Like receptor 7 agonist | 0.959 0.004 DBMET00997 | DBMET00997 | |
| 0.908 | 0.004 | 0.96 | Toll-Like receptor agonist | 0.96 0.004 DBMET00997 | DBMET00997 | |
| 0.862 | 0.002 | 0.927 | Phosphodiesterase 4D inhibitor | 0.927 0.002 DBMET00997 | DBMET00997 | |
| 0.849 | 0.002 | 0.936 | Phosphodiesterase 4B inhibitor | 0.936 0.002 DBMET00997 | DBMET00997 | |
| 0.833 | 0.003 | 0.957 | Phosphodiesterase inhibitor | 0.957 0.003 DBMET00997 | DBMET00997 | |
| 0.761 | 0.004 | 0.825 | Tumour necrosis factor alpha release inhibitor | 0.825 0.004 DBMET00997 | DBMET00997 | |
| 0.691 | 0.002 | 0.868 | Phosphodiesterase 4A inhibitor | 0.868 0.002 DBMET00997 | DBMET00997 | |
| 0.647 | 0.003 | 0.761 | Phosphodiesterase 4C inhibitor | 0.761 0.002 DBMET00997 | DBMET00997 | |
| 0.571 | 0.004 | 0.665 | Tumour necrosis factor antagonist | 0.665 0.003 DBMET00997 | DBMET00997 | |
| 0.61 | 0.051 | 0.614 | Antiinflammatory | 0.614 0.05 DBMET00997 | DBMET00997 | |
| 0.474 | 0.005 | 0.62 | Bronchodilator | 0.62 0.004 DBMET00997 | DBMET00997 | |
| 0.394 | 0.04 | 0.394 | Nootropic | 0.246 0.112 DBMET00997 | ||
| 0.429 | 0.076 | 0.429 | Cyclophilin D inhibitor | 0.36 0.115 DBMET00997 | ||
| 0.406 | 0.082 | 0.406 | Analgesic | 0.28 0.158 DBMET00997 | ||
| 0.344 | 0.054 | 0.344 | Calcium channel activator | 0.284 0.108 DBMET00997 | ||
| 0.297 | 0.031 | 0.297 | 5 Hydroxytryptamine 1E antagonist | 0.264 0.06 DBMET00997 | ||
| 0.256 | 0.004 | 0.256 | Janus tyrosine kinase 1 inhibitor | 0.18 0.006 DBMET00997 | ||
| 0.252 | 0.006 | 0.252 | CF transmembrane conductance regulator agonist | 0.217 0.014 DBMET00997 | ||
| 0.291 | 0.045 | 0.291 | Tyrosine kinase inhibitor | |||
| 0.261 | 0.023 | 0.261 | 3C-like protease (Human coronavirus) inhibitor | 0.136 0.129 DBMET00997 | ||
| 0.243 | 0.008 | 0.243 | Janus tyrosine kinase 2 inhibitor | 0.106 0.033 DBMET00997 | ||
| 0.232 | 0.009 | 0.232 | Nav1.5 sodium channel blocker | 0.119 0.056 DBMET00997 | ||
| 0.232 | 0.019 | 0.232 | Sodium channel (voltage-gated) blocker | 0.11 0.097 DBMET00997 | ||
| 0.238 | 0.044 | 0.238 | I kappa B kinase epsilon inhibitor | |||
| 0.2 | 0.008 | 0.2 | Nav1.8 sodium channel blocker | 0.126 0.019 DBMET00997 | ||
| 0.206 | 0.034 | 0.248 | Cytokine production inhibitor | 0.248 0.024 DBMET00997 | DBMET00997 | |
| 0.203 | 0.031 | 0.203 | Sodium channel blocker | |||
| 0.176 | 0.007 | 0.176 | Interleukin 5 antagonist | 0.153 0.01 DBMET00997 | ||
| 0.22 | 0.06 | 0.256 | Nitric-oxide synthase stimulant | 0.256 0.029 DBMET00997 | DBMET00997 | |
| 0.283 | 0.129 | 0.283 | Antiobesity | |||
| 0.213 | 0.061 | 0.286 | Non-steroidal antiinflammatory agent | 0.286 0.031 DBMET00997 | DBMET00997 | |
| 0.148 | 0.005 | 0.148 | Secretase beta inhibitor | 0.091 0.024 DBMET00997 | ||
| 0.188 | 0.058 | 0.212 | Antipruritic | 0.212 0.041 DBMET00997 | DBMET00997 | |
| 0.139 | 0.011 | 0.139 | Amidase inhibitor | 0.082 0.036 DBMET00997 | ||
| 0.139 | 0.016 | 0.139 | Glutamate (mGluR7) agonist | 0.096 0.069 DBMET00997 | ||
| 0.171 | 0.054 | 0.171 | Vascular endothelial growth factor 3 antagonist | |||
| 0.259 | 0.143 | 0.291 | Calpain 2 inhibitor | 0.291 0.12 DBMET00997 | DBMET00997 | |
| 0.114 | 0.003 | 0.114 | Vanilloid 3 antagonist | 0.058 0.005 DBMET00997 | ||
| 0.122 | 0.017 | 0.122 | Nicotinic alpha4beta2 receptor antagonist | |||
| 0.117 | 0.012 | 0.117 | NMDA 2B receptor antagonist | 0.089 0.018 DBMET00997 | ||
| 0.122 | 0.019 | 0.122 | Prostaglandin-E synthase inhibitor | |||
| 0.145 | 0.048 | 0.145 | Sphingosine 1-phosphate receptor 2 antagonist | 0.114 0.112 DBMET00997 | ||
| 0.12 | 0.029 | 0.12 | ALK inhibitor | |||
| 0.13 | 0.041 | 0.13 | Proto-oncogene tyrosine-protein kinase Kit inhibitor | |||
| 0.176 | 0.092 | 0.176 | Growth factor agonist | |||
| 0.088 | 0.005 | 0.088 | Farnesoid X receptor agonist | 0.072 0.007 DBMET00997 | ||
| 0.122 | 0.039 | 0.122 | Hedgehog signaling inhibitor | |||
| 0.092 | 0.019 | 0.092 | Orexin receptor 1 antagonist | |||
| 0.076 | 0.01 | 0.076 | Antiviral (Hepatitis D) | 0.062 0.02 DBMET00997 | ||
| 0.083 | 0.023 | 0.083 | Orexin receptor antagonist | |||
| 0.123 | 0.067 | 0.123 | Sphingosine 1-phosphate receptor 4 antagonist | 0.118 0.076 DBMET00997 | ||
| 0.085 | 0.03 | 0.085 | Nav1.7 sodium channel blocker | |||
| 0.103 | 0.05 | 0.103 | Potassium channel (Voltage-sensitive) activator | |||
| 0.069 | 0.02 | 0.069 | Diacylglycerol O-acyltransferase inhibitor | |||
| 0.284 | 0.236 | 0.284 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | |||
| 0.088 | 0.041 | 0.088 | Rho-associated kinase inhibitor | |||
| 0.08 | 0.035 | 0.08 | Potassium channel (Tandem pore domain) blocker | |||
| 0.057 | 0.012 | 0.057 | Glutamate (mGluR group II) antagonist | |||
| 0.051 | 0.009 | 0.051 | Free fatty acid receptor 1 antagonist | 0.037 0.019 DBMET00997 | ||
| 0.141 | 0.103 | 0.141 | Interleukin-1 receptor-associated protein kinase 1 inhibitor | |||
| 0.106 | 0.069 | 0.106 | EphA2 antagonist | |||
| 0.088 | 0.052 | 0.088 | Myeloperoxidase inhibitor | |||
| 0.126 | 0.092 | 0.126 | Death-associated protein kinase 1 inhibitor | |||
| 0.208 | 0.175 | 0.208 | Ca(v)3.3 blocker | |||
| 0.041 | 0.011 | 0.041 | Glutamate (mGluR2) antagonist | |||
| 0.058 | 0.031 | 0.058 | Melanin-concentrating hormone receptor 1 antagonist | |||
| 0.036 | 0.012 | 0.036 | Prostaglandin EP4 antagonist | |||
| 0.051 | 0.028 | 0.051 | Carnitine palmitoyltransferase 1B inhibitor | 0.044 0.041 DBMET00997 | ||
| 0.074 | 0.051 | 0.074 | Rho-associated kinase II inhibitor | |||
| 0.075 | 0.057 | 0.075 | Sphingosine 1-phosphate receptor antagonist | |||
| 0.103 | 0.085 | 0.103 | Beta amyloid protein antagonist | |||
| 0.054 | 0.037 | 0.054 | Protein kinase C epsilon inhibitor | |||
| 0.024 | 0.008 | 0.024 | Cyclin T1 inhibitor | |||
| 0.021 | 0.005 | 0.021 | Prokineticin receptor 1 antagonist | 0.02 0.007 DBMET00997 | ||
| 0.038 | 0.022 | 0.038 | Orexin receptor 2 antagonist | |||
| 0.085 | 0.071 | 0.085 | Polo-like kinase-1 inhibitor | |||
| 0.088 | 0.074 | 0.088 | Toll-Like receptor 3 antagonist | |||
| 0.067 | 0.054 | 0.096 | NMDA 2 receptor antagonist | 0.096 0.034 DBMET00997 | DBMET00997 | |
| 0.037 | 0.025 | 0.037 | Delayed rectifier potassium channel activator | |||
| 0.037 | 0.025 | 0.037 | Potassium channel KCNQ activator | |||
| 0.034 | 0.021 | 0.034 | Calcium release-activated channel blocker | |||
| 0.032 | 0.02 | 0.032 | Prostaglandin agonist | 0.028 0.026 DBMET00997 | ||
| 0.049 | 0.037 | 0.049 | Prostaglandin E2 antagonist | |||
| 0.02 | 0.009 | 0.02 | Complement factor D inhibitor | |||
| 0.086 | 0.077 | 0.086 | Sphingomyelinase inhibitor | |||
| 0.023 | 0.016 | 0.023 | Prostaglandin E2 agonist | |||
| 0.041 | 0.035 | 0.041 | Phosphodiesterase 3B inhibitor | |||
| 0.076 | 0.071 | 0.076 | Stem cell growth factor agonist | |||
| 0.032 | 0.027 | 0.032 | Carnitine palmitoyltransferase 1 inhibitor | |||
| 0.054 | 0.049 | 0.054 | Sphingosine 1-phosphate receptor 3 antagonist | |||
| 0.055 | 0.05 | 0.055 | TRPA1 antagonist | |||
| 0.055 | 0.051 | 0.055 | Ca(v)3.2 blocker | |||
| 0.031 | 0.028 | 0.031 | Carnitine palmitoyltransferase inhibitor | |||
| 0.112 | 0.109 | 0.112 | Vanilloid 1 agonist | |||
| 0.026 | 0.024 | 0.026 | Carnitine palmitoyltransferase 1A inhibitor | |||
| 0.055 | 0.054 | 0.055 | Protease activated receptor antagonist | |||
| 0.064 | 0.063 | 0.064 | Vanilloid antagonist | |||
| 0.082 | 0.089 | 0.098 | Gastric antisecretory | 0.098 0.069 DBMET00997 | DBMET00997 | |
| 0.185 | 0.201 | 0.217 | Apoptosis antagonist | 0.217 0.159 DBMET00997 | DBMET00997 | |
| 0.04 | 0.07 | 0.053 | Phosphodiesterase 7A inhibitor | 0.053 0.033 DBMET00997 | DBMET00997 | |
| 0.053 | 0.113 | 0.07 | Phosphodiesterase VIII inhibitor | 0.07 0.053 DBMET00997 | DBMET00997 | |
| 0.027 | 0.117 | 0.067 | Acetylcholine M3 receptor antagonist | 0.067 0.034 DBMET00997 | DBMET00997 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |